T. Sumiyoshi

发表

Correction: Next Generation MUT-MAP, a High-Sensitivity High-Throughput Microfluidics Chip-Based Mutation Analysis Panel

Rajesh Patel, R. Desai, R. Raja, 2014, PLoS ONE.

Next Generation MUT-MAP, a High-Sensitivity High-Throughput Microfluidics Chip-Based Mutation Analysis Panel

Rajesh Patel, R. Desai, R. Raja, 2014, PloS one.

Nonmyeloablative Conditioning Regimen to Increase Engraftment of Gene-modified Hematopoietic Stem Cells in Young Rhesus Monkeys.

D. Elashoff, D. Kohn, A. Tarantal, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer

O. Krijgsman, D. Peeper, L. Amler, 2019, PloS one.

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer

P. Hegde, L. Molinero, B. Vennapusa, 2020, Applied immunohistochemistry & molecular morphology : AIMM.

Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system.

G. Crooks, D. Kohn, P. Cannon, 2009, Human gene therapy.

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma

S. Wingert, A. M. Ovacik, D. E. de Almeida Nagata, 2022, Leukemia.

A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer

Z. Modrušan, H. Koeppen, F. D. de Sauvage, 2019, Clinical Cancer Research.

Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.

G. Hampton, P. Hegde, W. Forrest, 2014, The oncologist.

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population

G. Hampton, J. Fridlyand, T. Wilson, 2016, npj Breast Cancer.

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project

A. Warth, A. Marchetti, L. Bubendorf, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology

G. Hampton, J. Fridlyand, P. Hegde, 2018, npj Precision Oncology.

A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types

G. Hampton, D. Kirouac, L. Amler, 2018, npj Precision Oncology.

CpeR is an activator required for expression of the phycoerythrin operon (cpeBA) in the cyanobacterium Fremyella diplosiphon and is encoded in the phycoerythrin linker‐polypeptide operon (cpeCDESTR)

A. C. Clark, I. D'Silva, Manman Chu, 2002, Molecular microbiology.

Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents

M. Belvin, L. Molinero, D. Sampath, 2018, Blood.

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

R. Fonseca, A. Krishnan, S. Trudel, 2020 .

Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing

Thomas D. Wu, Genee Y. Lee, D. Danilenko, 2017, Cancer cell.

Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication.

D. Kohn, F. Dorey, I. Bahner, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

A Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia

Connie Y. C. Ma, N. Daver, K. Yee, 2021, American journal of hematology.

Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Sean P. Lear, S. Trudel, H. Koeppen, 2020 .

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples

G. Hampton, J. Fridlyand, T. Wilson, 2014, Breast Cancer Research and Treatment.

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

R. Fonseca, A. Krishnan, S. Trudel, 2021, Blood.

Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma

Connie Y. C. Ma, R. Meng, J. Grogan, 2016 .

Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients

Connie Y. C. Ma, A. Logan, B. Gjertsen, 2021, European journal of haematology.

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers

G. Hampton, T. Wilson, J. Spoerke, 2014, PloS one.

Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

V. Choeurng, T. Plesner, A. Vangsted, 2023, Clinical Hematology International.

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

R. Fonseca, A. Krishnan, S. Trudel, 2022, Blood.

CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.

S. Trudel, R. Vij, D. Samineni, 2022, Journal of Clinical Oncology.

A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

V. Choeurng, T. Plesner, A. Vangsted, 2021, Blood.

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer (UBC)

P. Hegde, T. Powles, D. Petrylak, 2014 .

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

P. Hegde, T. Powles, D. Petrylak, 2014, Journal of Immunotherapy for Cancer.

Abstract POSTER-THER-1441: Biomarker evaluation of phase 1 clinical trials of antibody-drug conjugates (ADCs) in platinum resistant ovarian cancer

Yulei N. Wang, Y. Guan, D. Shames, 2015 .